Chemoimmunotherapy Combined With Autologous NK Cell Therapy for Pediatric Patients With Refractory and Relapsed High-Risk Neuroblastoma and Ganglioneuroblastoma

NCT07375563 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

5

Enrollment

OTHER

Sponsor class

Conditions

Neuroblastoma (NB)
Ganglioneuroblastoma

Interventions

COMBINATION_PRODUCT: Dinutuximab beta, temozolomide, irinotecan, autologous NK cell
COMBINATION_PRODUCT: irinotecan, temozolomide, dinutuximab beta, NK-cell product

Sponsor

Federal Research Institute of Pediatric Hematology, Oncology and Immunology